• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Avalo Therapeutics, Inc. - Common Stock (NQ:AVTX)

7.450 -4.810 (-39.23%)
Delayed Quote Updated: 4:00 PM EDT, Oct 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 26,169,101
Open 8.990
Bid (Size) 7.400 (100)
Ask (Size) 7.500 (100)
Prev. Close 12.26
Today's Range 6.850 - 9.350
52wk Range 11.21 - 24.27
Shares Outstanding 96,008,951
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Top US Stock Gainers and Losers for the Oct. 22, 2026 Session ↗
Today 15:00 EDT
Via Chartmill
Top Gainers and Losers in Today's US Session ↗
Today 12:30 EDT
Via Chartmill

Performance

52-Week Range 69.3% below 52-week high
7.450
11.2152W Low 24.2752W High
1 Week 43.5% below 1-week high
11.211W Low 13.181W High

Avalo Therapeutics, Inc. - Common Stock (AVTX) traded between $11.21 and $24.27 over the past 52 weeks and last traded at $7.45, 69.3% below its 52-week high. Over the past week it ranged between $11.21 and $13.18.

Past 12 Months
-38.0%
-53.9%
-59.0%
-48.6%
-56.2%
-57.3%
1W -$4.56
1M -$8.72
3M -$10.70
6M -$7.05
YTD -$9.57
1Y -$9.98

AVTX was -57.3% over the past year, -48.6% over six months, -56.2% year to date, -38.0% in the last week.

12 Months vs Market
AVTX
-57.3%
DIA
+12.5%
SPY
+13.8%
QQQ
+15.2%
IWM
+12.0%

Over the past 12 months AVTX returned -57.3% versus DIA (Dow) +12.5%, SPY (S&P 500) +13.8%, QQQ (Nasdaq 100) +15.2% and IWM (Russell 2000) +12.0%.

Volume & Liquidity 27.07× 3-mo avg
Today 26,169,101 3-mo avg 966.9K
1W
1.4M
1M
1.1M
3M
966.9K
6M
1.5M
YTD
1.1M
1Y
991.9K

AVTX most recently traded 26,169,101 shares against a 3-month average daily volume of 966.9K.

More News

Read More
Gap-Up and Gap-Down Stocks: US Movers on October 22, 2026 ↗
Today 10:30 EDT
Via Chartmill
News headline image
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
September 29, 2026
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress
September 23, 2026
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics to Participate in Upcoming Investor Conferences
September 03, 2026
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates
August 06, 2026
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics to Participate in the BTIG Biotechnology Conference
July 22, 2026
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum
July 07, 2026
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes
June 26, 2026
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics Appoints Ron Philip to Board of Directors
June 23, 2026
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody
June 16, 2026
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
May 22, 2026
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
May 13, 2026
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics Stock Soars After Positive LOTUS Trial Results ↗
May 06, 2026
Via Benzinga
Wednesday's session: gap up and gap down stocks ↗
May 06, 2026
Via Chartmill
These stocks are moving in today's pre-market session ↗
May 06, 2026
Via Chartmill
News headline image
Avalo Therapeutics Announces Pricing of $375 Million Public Offering
May 05, 2026
From Avalo Therapeutics
Via GlobeNewswire
Get insights into the top gainers and losers of Tuesday's after-hours session. ↗
May 05, 2026
Via Chartmill
News headline image
Avalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
May 05, 2026
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa
May 05, 2026
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics Purchases Optional Milestone Buyout
April 28, 2026
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates
March 23, 2026
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics to Participate in Upcoming Investor Conferences
February 24, 2026
From Avalo Therapeutics
Via GlobeNewswire
News headline image
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
February 18, 2026
From Avalo Therapeutics
Via GlobeNewswire

Frequently Asked Questions

Is Avalo Therapeutics, Inc. - Common Stock publicly traded?
Yes, Avalo Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Avalo Therapeutics, Inc. - Common Stock trade on?
Avalo Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Avalo Therapeutics, Inc. - Common Stock?
The ticker symbol for Avalo Therapeutics, Inc. - Common Stock is AVTX on the Nasdaq Stock Market
What is the current price of Avalo Therapeutics, Inc. - Common Stock?
The current price of Avalo Therapeutics, Inc. - Common Stock is 7.450
When was Avalo Therapeutics, Inc. - Common Stock last traded?
The last trade of Avalo Therapeutics, Inc. - Common Stock was at 10/22/26 04:00 PM ET
What is the market capitalization of Avalo Therapeutics, Inc. - Common Stock?
The market capitalization of Avalo Therapeutics, Inc. - Common Stock is 715.27M
How many shares of Avalo Therapeutics, Inc. - Common Stock are outstanding?
Avalo Therapeutics, Inc. - Common Stock has 715M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap